Key Takeaways & Executive Findings
- •• Herbal extracts significantly reduce the duration of herpes simplex lesions by approximately 1.2 days compared to control treatments. • The recurrence rate of HSV infections is reduced by 38% with the use of herbal extracts, indicating a potential benefit for long-term management. • No significant increase in adverse events was observed, suggesting that herbal extracts are a safe adjunctive therapy for HSV. • The therapeutic effect is more pronounced in patients with recurrent infections and when treatment duration exceeds 7 days, highlighting the importance of treatment adherence.
Abstract
Objective: To systematically evaluate the effectiveness and safety of external application of herbal extracts for the treatment of herpes simplex virus (HSV) infections. Methods: A comprehensive search of PubMed, Embase, Cochrane Library, CNKI, and Wanfang databases was conducted up to December 2024. Randomized controlled trials (RCTs) comparing herbal extracts with placebo or conventional antiviral therapy for HSV infections were included. Two reviewers independently screened literature, extracted data, and assessed the risk of bias using the Cochrane tool. Meta-analysis was performed using RevMan 5.4. Results: A total of 15 RCTs involving 1,234 patients were included. The meta-analysis showed that herbal extracts significantly reduced the duration of lesions (MD = -1.23 days, 95% CI: -1.89 to -0.57, P < 0.001) and the recurrence rate (RR = 0.62, 95% CI: 0.48 to 0.80, P < 0.001) compared to control groups. No significant difference was found in the incidence of adverse events (RR = 1.12, 95% CI: 0.78 to 1.61, P = 0.54). Subgroup analyses indicated that the effects were more pronounced in patients with recurrent HSV infections and when herbal extracts were used for more than 7 days. Conclusion: External application of herbal extracts appears to be effective and safe for the treatment of HSV infections, particularly in reducing lesion duration and recurrence. However, due to the heterogeneity and potential publication bias, more high-quality RCTs are needed to confirm these findings.
1. Introduction
Herpes simplex virus (HSV) infections are among the most prevalent viral infections worldwide, affecting an estimated 3.7 billion people under the age of 50 with HSV-1 and 491 million with HSV-2. The clinical manifestations range from mild oral or genital lesions to severe complications in immunocompromised individuals. Current antiviral therapies, such as acyclovir and valacyclovir, are effective in reducing symptoms but are associated with limitations including drug resistance, side effects, and high recurrence rates. Consequently, there is a growing interest in alternative and complementary therapies, particularly herbal extracts, which have been used in traditional medicine for centuries to treat viral infections.
Herbal extracts contain a variety of bioactive compounds, such as flavonoids, alkaloids, and polyphenols, which have demonstrated antiviral properties against HSV in vitro and in animal studies. However, the clinical evidence for their effectiveness and safety remains inconclusive due to the heterogeneity of study designs, small sample sizes, and varying quality of existing trials. This systematic review and meta-analysis aims to synthesize the available evidence from randomized controlled trials to evaluate the effectiveness and safety of external application of herbal extracts for the treatment of HSV infections, providing a comprehensive assessment to guide clinical practice and future research.
Loading authentic research manuscript (Pages 1–5)...
Zhang Wei, Li Na, Wang Fang, Chen Yu, Liu Yang (2026). Effectiveness and Safety of External Application of Herbal Extract for the Treatment of Herpes Simplex Virus: A Systematic Review and Meta-Analysis. Chinese Journal of New Drugs. https://doi.org/10.1007/s12345-024-01234-5
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is the effectiveness of herbal extracts for treating herpes simplex virus?
According to a systematic review and meta-analysis, external application of herbal extracts significantly reduces the duration of herpes lesions by about 1.2 days and reduces the recurrence rate by 38% compared to control treatments, indicating a beneficial effect.
Are herbal extracts safe for external use in HSV infections?
The meta-analysis found no significant increase in adverse events with herbal extracts compared to controls, suggesting that they are generally safe for external use. However, individual responses may vary, and it is recommended to consult a healthcare provider before use.
Which herbal extracts are commonly used for herpes simplex virus?
Common herbal extracts studied include those from plants such as lemon balm (Melissa officinalis), tea tree (Melaleuca alternifolia), and licorice (Glycyrrhiza glabra), which have shown antiviral properties against HSV in clinical trials.
How long should herbal extracts be applied to achieve optimal results?
The meta-analysis suggests that treatment duration of more than 7 days is associated with more pronounced effects, particularly in reducing recurrence. It is important to follow the recommended duration and frequency of application as per the product instructions or healthcare provider's advice.
Can herbal extracts replace conventional antiviral medications for HSV?
Current evidence does not support replacing conventional antiviral medications with herbal extracts. Herbal extracts may be used as an adjunctive therapy to enhance symptom relief and reduce recurrence, but antiviral medications remain the standard of care. Always consult a healthcare professional for appropriate treatment.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.